Introduction
Cancer is a disease characterized by a shift in the controlled mechanisms that govern cell proliferation and differentiation 1 . Malignancy is caused by abnormalities in cells, which might be due to inherited genes or caused by outside exposure of the body to chemicals, radiation, or even infectious agents 2, 3 . Several techniques have been adopted for the treatment and eradication of cancerous cells. These techniques involved surgery, radiation, immunotherapy, chemotherapy and chemoprevention. Ideal anticancer drugs would eradicate cancer cells without harming normal tissues. Unfortunately, no currently available agents meet this criterion, and clinical use of drugs involves a weighing of benefits against toxicity in a search of favorable therapeutic index 4 . Many of chemotherapeutic agents currently used in cancer therapy are agents which inhibit tumor growth by inhibiting the replication and transcription of DNA. The wide occurrence of the heterocycles in bioactive natural products made them important synthetic targets. Quinazolines represent a class of heterocyclic compounds of great importance in biological chemistry [5] [6] [7] [8] [9] [10] [11] .
Quinazolines are frequently used in medicine because of their wide spectrum of biological activities [5] [6] [7] [8] [9] [10] [11] . In the course of identifying various chemical substances which may serve as leads for designing novel antitumor agents, we are particularly interested in the present work with quinazoline derivatives which have been identified as a new class of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors 10, 11 . It is well known that quinazoline derivatives are potent inhibitors of epidermal growth factor receptor (EGFR) [12] [13] [14] [15] [16] [17] . The EGFR is cellular trans-membrane tyrosine kinases that are over-expressed in a significant number of human tumors (e.g., breast, ovarian, colon, renal, and prostate) 18, 19 . Overexpression of EGFR family receptors have been observed in these tumors, approximately in 60% of all tumors. A number of small molecule EGFR kinase inhibitors have been evaluated in cancer clinical trials [12] [13] [14] [15] [16] [17] [18] [19] . For example (Figure 1 ), anilinoquinazoline-containing compounds gefitinib (IressaTM), 13c-19 erlotinib (TarcevaTM), 15a lapatinib (TykerbTM, also known as GW-572016) and Vandetanib (ZactimaTM) were recently approved for the treatment of breast cancer and non-small-cell lung cancer 15b-17 . On the other hand, melanoma is the most aggressive type of skin cancer in which V600E-B-RAF kinase is over-expressed in 63% of all malignant melanomas 20a . Vemurafenib (PLX4032) is a drug which targets inhibition of V600E-B-RAF kinase 20a . In 2011, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of late-stage melanoma, so inhibition of V600E-B-RAF kinase is a very potential avenue for the treatment of melanoma 20a . Moreover, a series of salicylanilides were synthesized and their inhibitory activity against tyrosine kinases was determined. Some of them indeed have proven to be potent and selective EGFR tyrosine kinase inhibitors 20b ( Figure 1 ). Many more compounds are still under evaluation in clinical trials for the treatment of cancer 18b,19 . Continuing our studies on quinazoline derivatives as attractive candidates as antitumor agents 10b,11a,20b , we have designed a number of new quinazoline derivatives containing benzyl group with different fragments and biologically evaluated the in vitro antitumor activities (Figure 1 ). In the present study, the substitution pattern at the 6 and 7 positions of quinazoline pharmacophore was selected so as to confer different electronic environment that would affect the lipophilicity, and hence the activity of the target molecules. The objectives of forming these hybrids are an attempt to reach an active antitumor agent with potentiated activity and selectivity toward cancerous cells. Molecular docking methodology was used to identify the structural features required for the antitumor properties of these new series. Malaysia and structure refinement and resolve was carried out using SHELXS97 21a . Solvent evaporation was performed under reduced pressure using Buchan Rotatory Evaporator at the Pharmaceutical Chemistry Department, King Saud University, Riyadh, Saudi Arabia. Thin-layer chromatography was performed on precoated (0.25 mm) silica gel GF254 plates (E. Merck, Germany); compounds were detected with 254 nm UV lamp. Silica gel (60-230 mesh) was employed for routine column chromatography separations. Compounds 1-3 and 14-15 were prepared according to reported procedure 11b , while compounds 13 and 21 were prepared according to the reported method 7a,21b respectively.
Materials and methods

Chemistry
General procedure for the synthesis of 3-benzyl-2-mercaptosubstitutedquinazolin-4(3H)-one (1) (2) (3) (4) A mixture of substituted anthranilic acid (10 mmol) and benzylisothiocyanate (10 mmol, 1.49 g) in 30 ml absolute ethanol containing triethylamine (11 mmol, 1.1 g) was heated under reflux for 2 h. The reaction mixture was filtered while hot, the solvent was removed under reduced pressure and the solid obtained was dried and recrystallized from ethanol. 2, 115.9, 116.2, 125.0, 127.4, 127.6, 127.8, 128.7, 136.1, 137.0, 139.6, 159.8, 176 .0.
3-Benzyl-6-chloro-2-mercaptoquinazolin-4(3H)-one (2 3, 117.3, 118.4, 126.7, 127.4, 127.7, 128.6, 128.9, 136.0, 136.8, 138.4, 159.0, 1, 115.7, 116.1, 127.1, 127.3, 127.5, 128.6, 134.7, 137.1, 137.2, 137.6, 159.8, 175 .5. 48.6, 55.7, 56.0, 97.7, 106.7, 107.9, 126.8, 127.1, 128.1, 135.0, 136.8, 146.7, 155.3, 158.8, 174.3. MS: (M, 328) .
General procedure for the synthesis of compounds 5-12
A mixture of appropriate 2-mercapto-3-benzylquinazolin-4(3H)-one (1) (2 mmol) and/or the appropriate 2-chloro-N-phenylacetamide and/or phenyl 2-chloroacetate (2 mmol) in 15 ml acetone containing anhydrous potassium carbonate (3 mmol, 415 mg) was stirred at room temperature for 10-12 h. The reaction mixture was filtered, the solvent was removed under reduced pressure and the solid obtained was dried and recrystallized from ethanol. 4, 3, 47.8, 56.0, 61.0, 96.8, 119.6, 124.8, 126.7, 127.8, 128.0, 128.1, 128.8, 134.1, 134.5, 134.7, 135.0, 146.4, 153.3, 158.0, 161.3, 166.3. MS: (M, 491 ).
2-(
2-(3-Benzyl-6-chloro-4-oxo-3,4-dihydroquinazolin-2-ylthio)-N- (3,4,5-trimethoxyphenyl) 4, 3, 36.3, 47.8, 56.0, 61.0, 96.9, 119.3, 124.7, 127.4, 127.8, 128.1, 128.8, 134.1, 134.5, 134.9, 136.3, 137.1, 144.5, 153.3, 157.0, 161.4, 166.4. MS: (M, 505 ).
2-(3-Benzyl-6,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-ylthio)-N- (3,4,5-trimethoxyphenyl) 2, 47.8, 56.0, 56.4, 56.5, 61.0, 97.0, 105.6, 106.6, 112.7, 127.7, 128.0, 128.8, 134.1, 134.7, 135.0, 142.8, 148.9, 153.4, 155.6, 155.7, 160.9, 166.4. MS: (M, 551) . (3,4,5-trimethoxyphenyl) propanamide (9 17.7, 46.7, 47.0, 55.6, 60.0, 97.0, 118.8, 125.8, 126.2, 126.6, 126.7, 127.4, 128.6, 133.6, 134.9, 135.5, 146.7, 152.7, 156.2, 160.8, 169 .0. MS: (M, 505). 6, 48.8, 47.2, 55.6, 60.1, 96.8, 120.0, 125.6, 126.8, 127.5, 128.0, 128.6, 130.2, 133.5, 134.9, 135.0, 135.2, 145.4, 152.7, 157.0, 159.9, 169 .0. MS: (M, 539, M + 2, 541). 17.6, 20.7, 46.6, 46.8, 55.6, 60.0, 96.8, 118.5, 125.7, 125.9, 126.7, 127.4, 128.6, 133.5, 135.0, 135.6, 136.0, 136.2, 144.9, 152.9, 155.1, 160.7, 169.1. MS: (M, 519) . (3,4,5-trimethoxyphenyl) propanamide (12 17.6, 46.5, 46.8, 55.6, 55.7, 60.1, 96.8, 105.6, 106.7, 11.6, 126.7, 127.4, 128.5, 133.6, 135.1, 135.7, 143.1, 148.2, 152.7, 154.1, 155.0, 160.1, 169.2. MS: (M, 565) .
A mixture of 3-benzyl-2-mercapto-6-methylquinazolin-4(3H)-one (3) (10 mmol, 2.82 g) ethyl 2-bromoacetate (11 mmol, 1.84 g), and anhydrous potassium carbonate (12 mmol, 1.66 g) in (100 ml) dry acetone was stirred at room temperature for 6 h. The reaction mixture was filtered, the solvent was removed under reduced pressure, and the solid obtained was dried and 4, 61.5, 118.8, 126.2, 126.4, 127.2, 127.9, 129.0, 136.0, 136.4, 136.7, 145.2, 155.5, 161.2, 168.7 . MS: (M, 368). (15) A solution of the ethyl 2-(3-benzyl-6-methyl-4-oxo-3,4-dihydroquinazolin-2-ylthio)acetate (14) 2, 35.0, 47.3, 118.9, 126.3, 126.4, 127.2, 127.9, 129.0, 136.1, 136.3, 136.6, 145.2, 155.5, 161.3, 166.6 . MS: (M, 354).
A solution of acid hydrazide 15 (1 mmol, 354 mg) in methanol (10 mL) and the appropriate aldehyde (1 mmol) was stirred at room temperature for 12-15 h. The reaction mixture was washed with hexane, filtered and dried.
2- (3-benzyl-6-methyl-4-oxo-3,4-dihydroquinazolin-2-ylthio 2, 34.3, 47.3, 118.9, 126.3, 126.4, 127.2, 127.3, 127.5, 127.9, 129.0, 129.3, 130.5, 134.6, 136.1, 136.3, 136.6, 143.8, 145.3, 147.1, 155.7, 161.1, 164.0, 169.0, MS: (M, 422) . 2, 34.3, 47.3, 56.2, 112.3, 118.9, 121.1, 122.5, 125.9, 126.3, 127.2, 127.8, 129.0, 131.8, 132.0, 136.1, 136.6, 139.5, 142.6, 145.3, 155.7, 155.9, 158.1, 161.2, 163 .8, 169.1. (16) 25.3, 43.6, 46.7, 114.0, 115.6, 120.0, 126.1, 126.7, 126.9, 127.1, 127.3, 127.4, 127.5, 127.7 127.9, 128.7, 128.8, 129.4, 136.2, 136.6, 137.0, 137.7, 137.9, 145.6, 150.6, 154.6, 161.9, 162.4 
. MS: (M, 516).
2-Mercapto-5H- [1, 3, 4] thiadiazolo [2,3-b] quinazolin-5-one (20)
A solution of 3-benzyl-2-mercaptoquinazolin-4(3H)-one (13) (354 mg, 1 mmol), carbon disulphide (760 mg, 10 mmol) and potassium hydroxide (170 mg, 3 mol) in ethanol (10 ml) was stirred at room temperature for 4 h the reaction mixture was heated under reflux for 6 h. The reaction mixture was cooled and the solvent was evaporated under reduced pressure. 1, 113.7, 114.0, 125.0, 130.7, 145.1, 158.6, 173.8 
. MS: (M, 235).
2-(Methylthio)-5H- [1, 3, 4] thiadiazolo [2,3-b] quinazolin-5-one (21) A solution of 2-mercapto-5H- [1, 3, 4] thiadiazolo [2,3-b] quinazolin-5-one (20) (470 mg, 2 mmol), in 10 ml acetone containing anhydrous potassium carbonate (3 mmol, 415 mg) was stirred with iodomethane (426 mg, 3 mmol) at room temperature for 6 h. The reaction mixture was filtered, the solvent was removed under reduced pressure, and the solid obtained was washed with water, dried and recrystallized from ethanol. Yield 76%; m.p. 
Antitumor screening
A primary anticancer assay was performed for an approximately 60 human tumor cell line panel derived from nine neoplastic diseases, in accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute, Bethesda, MD [22] [23] [24] [25] [26] .
Docking methodology
Docking studies have been performed using MOE 2008 MOE .10 (2008 . Docking procedure was followed using the standard protocol implemented in MOE 2008.10 and the geometry of resulting complexes was studied using the MOE's Pose Viewer utility 27 .
Results and discussion
Chemistry
Synthesis of 2-mercapto-3-benzylquinazolin-4(3H)-one derivatives (1-4) as key intermediates was achieved by the reaction of various anthranilic acid with benzylisothiocyanate in absolute ethanol in 82-88% yield. Compounds 1-4 were treated with 2-chloro-N-(3,4,5-trimethoxyphenyl)acetamide or 3-chloro-N- (3,4,5-trimethoxyphenyl) propanamide in anhydrous acetone in the presence of potassium carbonate to give the corresponding 2-(quinazolin-2-ylthio)-N-(3,4,5-trimethoxyphenyl)acetamide or 2-(quinazolin-2-ylthio)-N- (3,4,5-trimethoxyphenyl) propanamide 5-12 in 84-92% yield (Scheme 1).
On the other hand, 3-benzyl-2-mercapto-6-methylquinazolin-4(3H)-one (3) was reacted with ethyl 2-bromoacetate in dry acetone in the presence of potassium carbonate at room temperature to afford ethyl 2-(3-benzyl-6-methyl-4-oxo-3,4-dihydroquinazolin-2-ylthio)acetate (14), which was treated with hydrazine hydrate in ethanol at room temperature to furnish 2-(3-benzyl-6-methyl-4-oxo-3,4-dihydroquinazolin-2-ylthio) acetohydrazide (15) as key intermediate in 90% yield. Schiff's bases 16-18 were obtained in 90-92% yields, by reaction of the acid hydrazide 15 with various aldehydes in methanol at room temperature, compound 16 was subjected cyclization via boiling with acetic acid containing thioglycolic acid to give 2-phenylthiazolidin-4-one 19 in 61% yield. Reaction of 3-amino-2-mercaptoquinazolin-4(3H)-one (13) with carbon disulfide in ethanol containing potassium hydroxide gave 2-mercapto-5H- [1, 3, 4] thiadiazolo [2,3-b] quinazolin-5-one (20) in 90% yield, the last compound was alkylated by stirring with iodomethane in acetone containing potassium carbonate to yield 2-(methylthio)-5H- [1, 3, 4] thiadiazolo [2,3-b] quinazolin-5-one (21) in 76% yield. The structure of compound 21 was also confirmed by X-ray crystallography analysis 21b (Scheme 2) and the molecular solid state structure and numbering system are indicated in Figure 2 .
Antitumor activity
In vitro antitumor evaluation of eight compounds indicated in Table 1 was selected by National Cancer Institute, Bethesda, Maryland, USA, on the basis of degree of the structure variation and computer modeling techniques for evaluation of their anticancer activity.
A single dose (10 mM) of the test compounds 5-11 and 21 was used in the full NCI 60 cell lines panel assay [22] [23] [24] [25] [26] . The data reported as mean-graph of the percent growth of the treated cells, and presented as percentage growth inhibition (GI %) caused by the test compounds (Table 1) . The compounds 5-11 displayed significant activities in the in vitro screening on the tested cell lines in 10 mM concentration with positive cytotoxic effect (PCE) of 23/53, 52/53, 52/53, 49/49, 41/57, 46/57 and 46/58, respectively, whereas 7/58 for compound 21 (Table 2 ). Compounds 5-11 showed cytotoxic effects on the most of the cancer cell lines with mean growth inhibition percentages (MGI %) of 10%, 35%, 44%, 50%, 19%, 29% and 34%, respectively ( Table 2) . Compound 21 showed slight selective activity against HOP-62, NCI-H226, NCI-H522, SNB-75, OVCAR-4, PC-3 and MCF7 cancer cell lines with GI values of 13%, 20%, 11%, 28%, 11%, 11% and 21%, respectively (Table 1) .
With regard to broad spectrum antitumor activity, close examination of the data presented in Table 1 , revealed that compounds 7, 8 and 11 are the most active members of this study, showing effectiveness toward numerous cell lines belong to different tumor subpanels. Consequently, compounds 7, 8 and 11 were selected and tested against a panel of 60 different tumor cell lines at a 5-log dose range [22] [23] [24] [25] [26] . Three response parameters, GI 50 , TGI, and LC 50 were calculated for each cell line, using the known drug 5-Fluorouracil (5-FU) as a positive control. (Table 3) . Comparison of the antitumor activities of compounds 7, 8 and 11 with the activities of Gefitinib and Erlotinib showed that compounds 7, 8 and 11 (Table 4) possess activities almost equal to or higher than those of gefitinib and erlotinib against most cell lines except non-small lung (EKVX and NCI-H522), melanoma (SK-MEL-28), ovarian cancer (IGROV1 and SK-OV-3) renal cancer (ACHN and TK-10) and breast cancer (MDA-MB-468). On the other hand, compounds 6 and 10 yielded selective activities toward CNS, renal and breast cancer cell lines, compound 9 showed selective activities toward leukemia cell lines, whereas compound 5 possessed moderate antitumor activity.
Regarding the activity toward individual cell lines, compounds 9 and 10 showed selective activity against leukemia cell lines CCRF-CEM, K-562, MOLT-4 and PRMI-8226 with GI values of 26%, 22%, 19%, 23%, 31%, 40% and 44%, 58% respectively. Compound 10 revealed selective activities towards SR leukemia cell lines with GI values of 34%, whereas compound 11 disclosed weak activity against K-562 and PRMI-8226 cell lines with GI values of 23% and 17%.
In non-small cell lung, A549/ATCC cell line proved to be selectively sensitive to 6, 7, 8, 9, 10 and 11 with GI values of 33%, 34%, 72%, 28%, 41% and 58%, respectively. In addition, compounds 5, 10 and 11 proved to susceptible to the HOP-62, NCI-H226 and NCI-H522 cell lines with GI values of 35%, 43%, 91%, 45%, 69%, 73%, 30%, lethal and 35%, respectively. Compounds 6, 7 and 8 have dedicated activity against NCI-H226, NCI-H23, NCI-H322M and NCI-H460 cell lines with GI values of 54%, lethal, 55%, 24%, 26%, 31%, 18%, 37%, 35%, 36%, 43% and 32% respectively. Compounds 7 and 9 showed strong activity against HOP-92 and NCI-H522 cell lines in 76%, 46%, 69% and 96% respectively, Meanwhile, compounds 10 and 11 showed certain activity against NCI-H322M and NCI-H460 cell lines in 17%, 29%, 19% and 52% respectively, whereas compounds 7, 8 and 9 showed activity in 55%, 25% and 25% against HOP-62, EKVX and NCI-H322M cancer cells respectively.
In activity against colon cancer, compounds 6, 7, 8, 10 and 11 showed GI values of 49%, 57%, 48%, 48%, 66%, 44%, 30%, 39%, 24% and 22% with colon HCT-116 and HT29 cell lines, respectively, while compounds 7 and 8 demonstrated moderate activities against HCC-2998 cancer cell line with GI value 25% and 23%, respectively. On the other hand, compounds 10 and 11 verified sensitivity in 28% and 24% to colon HCT-15 cancer cells, compounds 6, 7 and 8 displayed modest activities against KM12 cancer cell with GI value 49%, 43% and 23% respectively.
In investigation of activity toward CNS cancer, compounds 5, 6, 7, 8, 9, 10 and 11 showed strong potency against CNS cancer SF-539, SNB-75 and U251 cell lines with GI values of 46%, lethal, 89%, 94%, 28%, 74%, 67%, 23%, 47%, lethal, lethal, 45%, 74%, lethal, 25%, 45%, 43%, 94%, 20%, 30 and 56%, respectively. Compounds 7, 8, 9 and 11 showed GI values of 31%, 61%, 19%, 60%, 21%, 55%, 25% and 41% to CNS cancer SF-268 and SF-295 cell lines, respectively. CNS cancer SNB-19 proved to be sensitive to compounds 8 and 11 with GI values of 37% and 27%, while compounds 6 and 10 showed certain potency to SF-268, and SF-295 cancer cells with GI values of 41% and 34% respectively. In activity against melanoma, compounds 6, 7 and 8 are active against LOX IMVI, MALME-3M, M14, MDA-MB-435, MDA-MB-435, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257 and UACC-62 cell lines with GI values from 22% to 80%. Compound 5 showed moderate activities against M14 cell line in 22% and 25%, whilst compounds 9 and 10 possessed activity against UACC-62 cell line with GI values of 34% and 47%. Melanoma SK-MEL-2, SK-MEL-28 and UACC-257 cell lines were sensitive to compounds 10 and 11 in 27%, 48%, 30%, 27%, 39% and 43%, respectively, at the same time as compound 11 was active to LOX IMVI and MALME-3M cell lines in 29% and 67%, while compound 10 had slight activity against SK-MEL-5 cell line with GI value of 26%.
In investigation of activity toward ovarian cancer, compounds 5, 6 and 7 showed moderate activities against ovarian OVCAR-8 and SK-OV-3 cell lines with GI values of 55%, 32%, 59%, 28%, 28% and 61% respectively. Ovarian OVCAR-3 and OVCAR-4 cell lines were responsive to compounds 6, 7 and 8 with GI values of 23%, 57%, 31%, 19%, 77% and 52% respectively, while compounds 9 and 10 were active against OVCAR-8 and OVCAR-4 cell lines with GI values of 21%, 27%, 37% and 39%, 
Compounds showed values 4100 mM. In renal cancer, compounds 6, 7, 8 and 11 were active against 786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10 and UO-31cell lines with GI values from 24%-lethal. Renal A498, ACHN, CAKI-1, SN12C and UO-31 cell lines were sensitive to compounds 9 and 10 with GI values of 36%, 65%, 22%, 55%, 28%, 37%, 18%, 21%, 55% and 26%, respectively, whereas RXF 393 cell line was responsive to compounds 5 and 10 with GI values of 29% and 43%, respectively.
Prostate PC-3 and DU-145 cell lines proved to be selectively sensitive to compounds 6, 7 and 8 with GI value of 29%, 26%, 65%, 28%, 20% and 46%, respectively, while compounds 9 and 10 possessed selective activity towards PC-3 cell line with GI value of 34% and 57%, respectively. Activity against breast cancer; breast MCF7, MDA-MB-231/ ATCC, HS 578T, BT-549, T-47D cell lines possessed convinced response to compounds 6, 7, 8, 9, 10 and 11 with GI values from 23% to 94%. Compound 5 showed GI effectiveness against breast HS 578T and BT-549 cell lines with values of 45% and 28%, additionally compound 11 had selective activity against breast MDA-MB-468 cell line with GI value of 32%.
Structure activity relationship
The antitumor activity correlation of the newly synthesized compounds (Figure 3 ) revealed that compound 5 showed moderate antitumor potency. The introduction of 6-Cl, 6-CH 3 or 6,7-dimethoxy groups at quinazoline moiety of compound 5 produced compounds 6-8 with dramatically increased the antitumor activity, also the induction of chloro or methyl function at position 6 of quinazoline nucleus of compound 9 produced compounds 10, 11 with remarkable improved antitumor potency. Additionally, replacement of the 6-Cl function at quinazoline ring of compounds 6 and 10 by 6-CH 3 group produced compounds 7 and 11 with significant enhanced antitumor activity, as well substitution of the 6-Cl-function at quinazoline nucleus of compound 6 with 6,7-dimethoxy functions gave compound 8 with advanced antitumor achievement, which implied that electron donating functions favor the activity rather than electron withdrawing moieties. Moreover, changeover of the 6-CH 3 group of quinazoline ring of compound 7 with 6,7-dimethoxy group enhanced the antitumor activity of compound 8. On the other hand, replacement of acetamide function of compounds 6-8 by propanamide function produced compounds 9-11 with reduction of the antitumor activity, which indicated that the length of the carbon chain linking is a vital factor for the antitumor activity. Accordingly, the N-substituted phenylacetamides with one carbon length favor the activity (compounds 6-8) rather than the propanamides with two carbon lengths (compounds 9-11).
Molecular docking studies
The level of antitumor activities of the compounds 7 and 8 over breast cancer, colon, renal and small lung cancer cells, in which EGFR kinase is highly expressed 18, 19, 27 , prompted us to perform molecular docking into the ATP binding site of EGFR kinases to predict if these compounds had analogous binding mode to the EGFR kinase inhibitor. We assumed that the active target 3-Benzyl-4(3H)quinazolinone analogues 9 compounds 7 and 8 might demonstrate antiproliferative activity against breast cancer, colon, renal and small lung cell lines through inhibition of EGFR. Compounds 7 and 8 were docked into receptor active site of EGFR along with their inhibitor. All calculations were performed using MOE 2008.10 software 28 installed on 2.0G Core 2 Duo. The crystal structure of EGFR with erlotinib (TarcevaÔ) (PDB code: 1M17) 18, 19, [29] [30] [31] was obtained from protein data bank (PDB). The automated docking program of MOE 2008.10 was used to dock compounds 7 and 8 along with the inhibitor erlotinib into ATP binding site of EGFR. The complexes were energy-minimized with a MMFF94 force field 31 till the gradient convergence 0.01 kcal/mol was reached. The binding energies of compounds 7, 8 and erlotinib docked into the active site of EGFR were À21.04, À22.56 and À24.00 kcal/mol, respectively ( Figure 4 ). These docking studies have revealed that the quinazoline ring binds to a narrow hydrophobic pocket in the N-terminal domain of EGFR-TK where N-1 of the quinazoline ring interacts with the backbone NH of Met-769 via a hydrogen bond, and similarly, a water (HOH-10) molecule-mediated hydrogen bonding interaction is observed among the N-3 and S-atom of the quinazoline ring and the Thr-830 and Thr-766 side chain. These interactions revealed the importance of quinazoline ring for binding and the subsequent inhibitory capacity. Compounds 7, 8 complexed with EGFR-TK in a fashion similar to erlotinib and showed the occurrence of three hydrogen bonds with Met-769-(2.94-2.98Å ) and HOH-10 (2.70-2.71Å and 2.98-2.99Å )-mediated hydrogen bonding interaction with Thr-830 and Thr-766 side chain. Moreover, the anilide trimethoxyphenyl fragment showed two additional hydrogen bonds with Gly-695 (2.74-2.73Å and 2.85-2.92Å ).
On the other hand, the level of antitumor activities of the compound 11 over melanoma cancer cells, in which V600E-B-RAF kinase is highly expressed 18, 19, 28 , prompted us to perform molecular docking into the ATP binding site of V600E-B-RAF kinase to predict if this compound 11 has analogous binding mode to the V600E-B-RAF kinase inhibitors. The crystal structure of V600E-BRAF kinase in complex with PLX4032 (PDB code: 3OG7) 28, 32, 33 was obtained from protein data bank (PDB). The binding energies of compound 11 and PLX4032 docked into the active site of V600E-BRAF kinase were À30.65 and À36.11 kcal/mol, respectively ( Figure 5 ). The docking study has revealed that the ligand 11 has bound in the active site of one of the protomers in the protein dimer through the formation of four hydrogen bonds with Gln-530 (2.85Å ), Cys-532 (2.92Å ), Leu-505 (2.13Å ) and Thr-529 (2.20Å ). Moreover, there was one areneinteraction between the binding site and the ligand which occurred between quinazoline fragment and Trp-531. The results of this molecular docking study can support the postulation that our active compound may inhibit the growth of melanoma cell lines through inhibition of B-RAF kinase, similar to PLX4032 33 . 
Conclusion
A new derivatives of 3-benzyl-4(3H)-quinazolinones were synthesized and evaluated for their in vitro antitumor activity. The results of this study indicated that compounds 7, 8 and 11 possess amazing broad spectrum antitumor activity with mean GI 50 (10.47, 7.24 and 14.12 mM respectively) and are nearly 1.5-3.0 fold more potent compared with the positive control 5-FU with mean GI 50 22.60 mM.
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